New IOF review provides guidance on fracture prevention in cancer-associated bone disease

PUBLIC RELEASE DATE:

1-Nov-2013

[


| E-mail

]


Share

Contact: L. Misteli
info@iofbonehealth.org
41-229-940-100
International Osteoporosis Foundation

International Osteoporosis Foundation Working Group outlines guidelines, treatment options and care pathways to help prevent osteoporosis and fractures in cancer patients

Nyon, Switzerland November 1, 2013

Cancer is a health burden of increasing importance which affects close to 13 million people globally. Bone is often affected in these patients, frequently because of bone metastases, or as a result of anti-cancer therapies which can contribute to bone loss and fragility.

A new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group reviews the epidemiology and pathophysiology of cancer-associated bone disease and provides information about fracture prevention in cancer patients. The review summarizes the pertinent recommendations of leading societies, providing guidance for clinical decision making and information on evidence-based pathways to prevent skeletal-related events and bone loss.

Cancer patients are at greater risk of bone disease and fractures:

Cancer-induced bone disease can result from the primary disease itself, either due to circulating bone resorbing substances, or from metastasis to bone such as commonly occurs with breast, lung and prostate cancer. As well, cancer therapy itself can cause bone loss and fractures especially in the case of glucocorticoid or estrogen deprivation therapy, chemotherapy-induced ovarian failure, and androgen deprivation therapy.

As people with cancer survive longer, cancer related bone disease and its treatment becomes an important health issue that needs to be addressed. For example, women undergoing therapy for breast cancer, without bone metastases, have been shown to have a fivefold higher prevalence of vertebral fractures than women without cancer of the same age. Men with prostatic cancer are at particularly high risk of osteoporosis and fracture due in part to treatment with androgen deprivation therapy. Rates of bone mineral density decrease can be as high as 3 to 5.6% within the first year of treatment alone.

Professor Ren Rizzoli, lead author and Professor of Medicine and Head of the Division of Bone Disease at the University Hospitals of Geneva stated, "Physicians must make a concerted effort to prevent bone loss and fractures in their patients. Fragility fractures due to osteoporosis can have serious repercussions, including severe pain, immobility, and accompanying loss of quality of life. Patients with cancer, including those who are in remission, should not have their quality of life further jeopardized by disability resulting from fractures."

Early evaluation and treatment for osteoporosis is critical:

Physicians should be aware that cancer patients are at heightened risk of fractures, and that bone-modifying agents, such as bisphosphonates and denosumab, are effective in preventing and delaying cancer-related bone disease.

"Recommendations for assessment and treatment with bone modifying therapies are highly targeted to the type of cancer, and depend on whether or not bone metastasis is involved and whether the bone loss is treatment induced. This IOF review gives physicians a comprehensive understanding of the key clinical considerations involved and directs attention to the recommendations of the expert societies in the field," said Professor Cyrus Cooper, Chair of the IOF Committee of Scientific Advisors.

###

R. Rizzoli, J.-J. Body, M.-L. Brandi, J. Cannata-Andia, D. Chappard, A. El Maghraoui,
C. C. Gler, D. Kendler, N. Napoli, A. Papaioannou, D. D. Pierroz, M. Rahme,
C. H. Van Poznak, T. J. de Villiers, G. El Hajj Fuleihan for the International Osteoporosis
Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease (2013) Cancer-associated bone disease. Osteoporos Int 2013 DOI 10.1007/s00198-013-2530-3
http://link.springer.com/article/10.1007/s00198-013-2530-3

The paper can be accessed free of charge until January 31, 2014

About IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers, leading companies, as well as more than 200 patient, medical and research societies, work together to make bone, joint and muscle health a worldwide heath care priority.

http://www.iofbonehealth.org;
http://www.facebook.com/iofbonehealth;
http://www.twitter.com/iofbonehealth

---

[


| E-mail


Share

]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

PUBLIC RELEASE DATE:

1-Nov-2013

[


| E-mail

]


Share

Contact: L. Misteli
info@iofbonehealth.org
41-229-940-100
International Osteoporosis Foundation

International Osteoporosis Foundation Working Group outlines guidelines, treatment options and care pathways to help prevent osteoporosis and fractures in cancer patients

Nyon, Switzerland November 1, 2013

Cancer is a health burden of increasing importance which affects close to 13 million people globally. Bone is often affected in these patients, frequently because of bone metastases, or as a result of anti-cancer therapies which can contribute to bone loss and fragility.

A new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group reviews the epidemiology and pathophysiology of cancer-associated bone disease and provides information about fracture prevention in cancer patients. The review summarizes the pertinent recommendations of leading societies, providing guidance for clinical decision making and information on evidence-based pathways to prevent skeletal-related events and bone loss.

Cancer patients are at greater risk of bone disease and fractures:

Cancer-induced bone disease can result from the primary disease itself, either due to circulating bone resorbing substances, or from metastasis to bone such as commonly occurs with breast, lung and prostate cancer. As well, cancer therapy itself can cause bone loss and fractures especially in the case of glucocorticoid or estrogen deprivation therapy, chemotherapy-induced ovarian failure, and androgen deprivation therapy.

As people with cancer survive longer, cancer related bone disease and its treatment becomes an important health issue that needs to be addressed. For example, women undergoing therapy for breast cancer, without bone metastases, have been shown to have a fivefold higher prevalence of vertebral fractures than women without cancer of the same age. Men with prostatic cancer are at particularly high risk of osteoporosis and fracture due in part to treatment with androgen deprivation therapy. Rates of bone mineral density decrease can be as high as 3 to 5.6% within the first year of treatment alone.

Professor Ren Rizzoli, lead author and Professor of Medicine and Head of the Division of Bone Disease at the University Hospitals of Geneva stated, "Physicians must make a concerted effort to prevent bone loss and fractures in their patients. Fragility fractures due to osteoporosis can have serious repercussions, including severe pain, immobility, and accompanying loss of quality of life. Patients with cancer, including those who are in remission, should not have their quality of life further jeopardized by disability resulting from fractures."

Early evaluation and treatment for osteoporosis is critical:

Physicians should be aware that cancer patients are at heightened risk of fractures, and that bone-modifying agents, such as bisphosphonates and denosumab, are effective in preventing and delaying cancer-related bone disease.

"Recommendations for assessment and treatment with bone modifying therapies are highly targeted to the type of cancer, and depend on whether or not bone metastasis is involved and whether the bone loss is treatment induced. This IOF review gives physicians a comprehensive understanding of the key clinical considerations involved and directs attention to the recommendations of the expert societies in the field," said Professor Cyrus Cooper, Chair of the IOF Committee of Scientific Advisors.

###

R. Rizzoli, J.-J. Body, M.-L. Brandi, J. Cannata-Andia, D. Chappard, A. El Maghraoui,
C. C. Gler, D. Kendler, N. Napoli, A. Papaioannou, D. D. Pierroz, M. Rahme,
C. H. Van Poznak, T. J. de Villiers, G. El Hajj Fuleihan for the International Osteoporosis
Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease (2013) Cancer-associated bone disease. Osteoporos Int 2013 DOI 10.1007/s00198-013-2530-3
http://link.springer.com/article/10.1007/s00198-013-2530-3

The paper can be accessed free of charge until January 31, 2014

About IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers, leading companies, as well as more than 200 patient, medical and research societies, work together to make bone, joint and muscle health a worldwide heath care priority.

http://www.iofbonehealth.org;
http://www.facebook.com/iofbonehealth;
http://www.twitter.com/iofbonehealth

---

[


| E-mail


Share

]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2013-11/iof-nir110113.php
Category: John Spano   Wojciech Braszczok   Ink Master   affordable care act   monday night football